fosamprenavir has been researched along with saquinavir in 8 studies
Studies (fosamprenavir) | Trials (fosamprenavir) | Recent Studies (post-2010) (fosamprenavir) | Studies (saquinavir) | Trials (saquinavir) | Recent Studies (post-2010) (saquinavir) |
---|---|---|---|---|---|
174 | 55 | 37 | 1,454 | 256 | 219 |
Protein | Taxonomy | fosamprenavir (IC50) | saquinavir (IC50) |
---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 1.9 | |
Bile salt export pump | Homo sapiens (human) | 3.9 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.016 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 2 (ISOLATE ROD) | 0.0084 | |
Gag polyprotein | HIV-1 M:B_MN | 0.0131 | |
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.05 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 1.5 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0066 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 4.273 | |
Substance-K receptor | Homo sapiens (human) | 6.214 | |
Thromboxane-A synthase | Homo sapiens (human) | 2.182 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 4.273 | |
Mu-type opioid receptor | Homo sapiens (human) | 9.625 | |
Kappa-type opioid receptor | Homo sapiens (human) | 6.951 | |
Exoribonuclease H | Human immunodeficiency virus 2 | 0.0005 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 1.9 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 1.9 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 1.9 | |
Genome polyprotein | Human rhinovirus sp. | 0.0005 | |
Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | 8.26 | |
Protease | Human immunodeficiency virus 1 | 0.0217 | |
Protease | Human immunodeficiency virus 1 | 0.0004 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
DeGoey, DA; Randolph, JT | 1 |
Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A | 1 |
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
Bogner, JR; Gyalrong-Steur, M; Seybold, U | 1 |
3 review(s) available for fosamprenavir and saquinavir
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
5 other study(ies) available for fosamprenavir and saquinavir
Article | Year |
---|---|
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
[FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners].
Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Ritonavir; Saquinavir; Sulfonamides | 2004 |
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolic Clearance Rate; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Saquinavir; Sulfonamides; Viral Load | 2004 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Cholesterol; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Retrospective Studies; Saquinavir; Sulfonamides | 2011 |